

Abstract number: Euro17A-POS0265

Abstract type: Poster

Reference: This abstract was presented at EuroPCR 2017, 16-19 May 2017, Paris

Link: <https://abstractbook.pcronline.com/export/pdf/id/265>

Published on: 16 May 2017

Long-term clinical outcomes following ultrathin, biodegradable polymer-coated sirolimus-eluting stent implantation in diabetic vs. non-diabetic patients: results from the SCODA registry

MIMISH L.(1), KHOJA A.L.(2), NADA A.(1), ALTNJI I.(1), MIMISH H.(1)

(1) King Abdulaziz University Hospital, Jeddah SAUDI ARABIA(2) King Fahad MOH Hospital, Jeddah SAUDI ARABIA

THEME: Coronary Interventions

TOPIC(S): Stents and scaffolds, Left main and multivessel disease, Other Coronary Interventions

AIMS

Aim of this registry was to compare the long-term (up to 7 years) clinical outcomes after implantation of the Supralimus-Core; ultrathin-strut (60 μ m), biodegradable polymer coated sirolimus-eluting stent (SES); in diabetic and non-diabetic patients.

METHODS AND RESULTS

We conducted a retrospective, single-arm, open-label, multicenter registry of 517 patients, who had treated exclusively with the Supralimus-Core SES (Sahajanand Medical Technologies Pvt. Ltd., Surat, India), between April-2008 and May-2015 at two centers in Saudi Arabia. Of these, 279 patients were diabetic, whereas 238 had non-diabetic. The primary endpoint was long-term (up to 7 years) combined major adverse cardiac events (MACE) including cardiac death, myocardial infarction (MI), target lesion revascularization (TLR), target vessel revascularization (TVR)/ coronary artery bypass graft (CABG) and stent thrombosis; according to ARC definitions. A total of 517 patients [279 (54.0%) diabetic patients and 238 (46.0%) non-diabetic patients], with mean age of 55.0 ± 10.2 years, were evaluated in this registry. Diabetic patients had a higher prevalence of arterial hypertension (59.5% vs. 39.9%, $p < 0.001$), hyperlipidemia (71.7% vs. 40.8%, $p < 0.001$) and unstable angina (40.9% vs. 29.8%, $p = 0.009$) compare to non-diabetic patients. There were no significant differences in lesion complexity like long lesions (≥ 30 mm), bifurcation lesions, calcified lesions, restenotic lesions, and total occlusion between diabetic and non-diabetic patients. A median follow-up of 5.6 years; interquartile range: 3 to 7 years was achieved in 95.6% of patients (494/517) and during follow-up, the cumulative incidence of MACE in patients with diabetes was comparable to that of non-diabetics [46 (17.2%) vs. 29 (12.8%), $p = 0.169$]. Diabetic patients had higher risks of cardiac death [25 (9.4%) vs. 9 (4.0%), $p = 0.018$] during follow-up compared with non-diabetic patients. However, the rates of TLR [15 (5.6%) vs. 15 (6.6%), $p = 0.656$] and TVR/CABG [4 (1.5%) vs. 5 (2.2%), $p = 0.560$] were not significantly different between diabetic and non-diabetic patients during follow-up. Also, there was no difference in stent thrombosis between diabetic and non-diabetic patients [2 (0.7%) vs. 0 (0), $p = 0.502$].

CONCLUSIONS

Despite complex lesion morphology, this registry demonstrates satisfactory and sustained long-term clinical outcomes as evidenced by the low rates of MACE, for the Supralimus-Core SES, in diabetic and non-diabetic patients.